Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39121437/
Revumenib led to high remission rates with a predictable safety profile in R/R KMT2Ar acute leukemia. To our knowledge, this trial represents the largest evaluation of a targeted therapy for...
The AUGMENT-101 trial shows revumenib achieves meaningful remission and high response rates in relapsed/refractory KMT2A-rearranged acute leukemia, with manageable safety, marking progress in targeted leukemia therapy.
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39121437/
Revumenib led to high remission rates with a predictable safety profile in R/R KMT2Ar acute leukemia. To our knowledge, this trial represents the largest evaluation of a targeted therapy for...
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39936576/
The availability of 12 newly approved agents has been welcomed; however, optimal strategies incorporating newer agents into therapeutic algorithms are debated. The overarching approach integrates patient and caregiver goals of...
Acute myeloid leukemia management has evolved with improved diagnostics, risk stratification, measurable residual disease monitoring, and incorporation of 12 new therapies, enabling more personalized, risk-adapted treatment strategies despite ongoing challenges.
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39121437/
Revumenib led to high remission rates with a predictable safety profile in R/R KMT2Ar acute leukemia. To our knowledge, this trial represents the largest evaluation of a targeted therapy for...
Revumenib showed significant efficacy and manageable safety in relapsed/refractory KMT2A-rearranged acute leukemia, achieving meaningful remission rates, high overall response, and measurable disease clearance in this phase II trial.
TP53-Mutated Acute Myeloid Leukemia: Unanswered Questions - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40459096/
TP53-mutated acute myeloid leukemia (AML) remains one of the most treatment-resistant hematologic malignancies, with poor overall survival despite advancements in therapeutic strategies. The loss of functional p53 compromises DNA repair,...
TP53-mutated AML is highly treatment-resistant, with poor survival despite chemotherapy, HMAs, venetoclax, and immunotherapies. Current strategies show limited efficacy, highlighting the urgent need for multi-targeted combination approaches and precision medicine.